After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi’s (NASDAQ:SNY) consumer healthcare unit Opella announced Tuesday that the U.S. FDA has lifted a clinical hold on a ...

French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an ...

The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

French pharma major Sanofi’s consumer healthcare business, Opella, has announced that the US Food and Drug Administration ...

Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Clarius Group LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 11.9% in the fourth quarter, ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory syncytial virus (RSV) antibody, Beyfortus (in partnership with AstraZeneca [AZN]), Pompe disease therapy ...